Agenus Inc (OQ:AGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3 Forbes Rd
LEXINGTON MA 02421-7305
Tel: N/A
Website: agenusbio.com
IR: See website
<
Key People
Garo H. Armen
Chairman of the Board, Chief Executive Officer, Co-Founder
Jennifer S. Buell
President, Chief Operating Officer
Christine M. Klaskin
Chief Accounting Officer, Vice President - Finance
Evan Kearns
Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary
Donald Vidic
Vice President - Head of Commercial
 
Business Overview
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Financial Overview
For the nine months ended 30 September 2020, AgenusInc revenues decreased 51% to $56.9M. Net loss applicableto common stockholders increased 84% to $143.5M. Revenuesreflect Research and development decrease of 70% to $24.3M,Other revenue decrease of 99% to $52K, Non-cash royaltyrevenue related to the decrease of less than 1% to $29.9M.Higher net loss reflects Non-cash interest expense increaseof 52% to $44.9M (expense).
Employees: 328 as of Feb 29, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $601.21M as of Sep 30, 2020
Annual revenue (TTM): $91.41M as of Sep 30, 2020
EBITDA (TTM): -$103.15M as of Sep 30, 2020
Net annual income (TTM): -$173.57M as of Sep 30, 2020
Free cash flow (TTM): -$138.97M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 190,149,301 as of Nov 5, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.